Serum neurofilament light as a biomarker in progressive multiple sclerosis

There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disability. The development of treatments may be accelerated if novel biomarkers are developed to overcome the limitations of traditional imaging outcomes revealed in early phase trials. In January 2019, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapoor, Raju, Smith, Kathryn E., Allegretta, Mark, Arnold, Douglas L., Carroll, William, Comabella, Manuel, Furlan, Roberto, Harp, Christopher, Kuhle, Jens, Leppert, David, Plavina, Tatiana, Sellebjerg, Finn, Sincock, Caroline, Teunissen, Charlotte E., Topalli, Ilir, von Raison, Florian, Walker, Elizabeth, Fox, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Views & Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538221/
https://www.ncbi.nlm.nih.gov/pubmed/32675076
http://dx.doi.org/10.1212/WNL.0000000000010346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538221/
https://www.ncbi.nlm.nih.gov/pubmed/32675076
http://dx.doi.org/10.1212/WNL.0000000000010346

Ejemplares similares